View More View Less
  • 1 Általános Orvostudományi Kar, Klinikai Központ, II. Belgyógyászati Klinika, Nephrologiai és Diabetológiai Centrum, Pécsi Tudományegyetem, Pécs, Pacsirta u. 1., 7624
Open access

Összefoglaló. A koronavírus-fertőzés 2019 végén indult útjára, lassan a Föld teljes lakosságát elérő pandémiaként. Egy olyan kórokozóról van szó, amely ilyen nagy számú megbetegedést még nem okozott, ezért annak természetes lefolyásáról, a szövődmények kialakulásáról és a kezelési lehetőségekről még keveset tudunk. Ennek következtében a kezdetben megjelent információk nagyon felületesek voltak, a következtetések nemritkán tévútra vezették mind az orvosokat, mind a betegeket. Az adatok gyarapodásával azonban egyre több kérdésre kapunk választ. Erre a folyamatra az egyik legreprezentánsabb példa az ibuprofén története, amely kezdetben tiltott, később tűrt terápiás szer volt, de ma már támogatott kezelési lehetőség a koronavírus-fertőzésben. Orv Hetil. 2020; 161(50): 2104–2106.

Summary. The coronavirus infection started in late 2019, as a pandemic slowly reaching the entire population of the earth. This pathogen has not yet caused such a large number of diseases, so little is known about its natural course, the development of complications, and treatment options. As a result, the information initially published was very superficial, and the conclusions often misled both physicians and patients. As the data grows, however, we get more and more questions answered. One of the most representative examples of this process is the history of ibuprofen, which was initially banned, thereafter tolerated, and is now a supported treatment option for coronavirus infection. Orv Hetil. 2020; 161(50): 2104–2106.

  • 1

    Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020; 8(4): e21. [Erratum: Lancet Respir Med. 2020; 8(6): e54.]

  • 2

    Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. BMJ 2020; 368: m1086.

  • 3

    Little P. Non-steroidal anti-inflammatory drugs and Covid-19. BMJ 2020; 368: m1185.

  • 4

    Weikle B. WHO clarifies guidance on ibuprofen, says there’s no evidence it can worsen COVID-19. Available from: https://www.cbc.ca/news/health/ibuprofen-covid-19-novel-coronavirus-1.5501496 [accessed: June 20, 2020].

  • 5

    Sodhi M, Etminan M. Safety of ibuprofen in patients with COVID-19: causal or confounded? Chest 2020; 158: 55–56.

  • 6

    GOV.UK. Commission on Human Medicines (CHM) advice on ibuprofen and coronavirus (COVID-19). Available from: https://www.gov.uk/government/news/commission-on-human-medicines-advice-on-ibuprofen-and-coronavirus-covid-19 [accessed: June 20, 2020].

  • 7

    Zolk O, Hafner S, Schmidt CQ. COVID-19 pandemic and therapy with ibuprofen or renin–angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments. Naunyn Schmiedebergs Arch Pharmacol. 2020; 393: 1131–1135.

  • 8

    Kutti Sridharan G, Kotagiri R, Chandiramani VH, et al. COVID-19 and avoiding ibuprofen. How good is the evidence? Am J Ther. 2020; 27: e400–e402.

  • 9

    MaassenVanDenBrink A, de Vries T, Danser AH. Headache medication and the COVID-19 pandemic. J Headache Pain 2020; 21: 38.

  • 10

    Moore N, Carleton B, Blin P, et al. Does ibuprofen worsen COVID-19? Drug Saf. 2020; 43: 611–461.

  • 11

    Rinott E, Kozer E, Shapira Y, et al. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin Microbiol Infect. 2020; 26: 1259.e5–1259.e7.

  • 12

    Vosu J, Britton P, Howard-Jones A, et al. Is the risk of ibuprofen or other non-steroidal anti-inflammatory drugs increased in COVID-19? J Paediatr Child Health 2020; 56: 1645–1646.

  • 13

    Smart L, Fawkes N, Goggin P, et al. A narrative review of the potential pharmacological influence and safety of ibuprofen on coronavirus disease 19 (COVID-19), ACE2, and the immune system: a dichotomy of expectation and reality. Inflammopharmacology 2020; 28: 1141–1152.

  • 14

    Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non-steroidal anti-inflammatory drugs who tested positive for SARS-CoV-2: a Danish nationwide cohort study. PLoS Med. 2020; 17: e1003308.

  • 15

    European Medicnes Agency. Assessment report for non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. Available from: https://www.ema.europa.eu/en/documents/referral/assessment-report-article-53-procedure-non-steroidal-anti-inflammatory-drugs-nsaids-cardiovascular_en.pdf [accessed: June 20, 2020]

  • 16

    European Medicines Agency. Updated advice on use of high-dose ibuprofen. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500185426.pdf [accessed: June 20, 2020].

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1266 1266 43
PDF Downloads 1944 1944 92